地舒单抗治疗超过3年可进一步降低非椎体骨折风险:长达10年随访结果
FREEDOM试验及其开放标签延长研究纳入4074例绝经后骨质疏松女性,评估地舒单抗治疗≤10年对非椎体骨折(NVF)的影响。与治疗第1~3年相比,第4~7年NVF发生率显著降低(RR 0.72,P<0.001),长期组第4~10年亦显著降低(RR 0.74,P=0.008)。
要点
- 颌骨坏死合并非典型股骨骨折发生率低(0.06/100受试者年)。
核心结论
- 地舒单抗治疗超过3年并长达10年,与治疗前3年相比可进一步降低非椎体骨折发生率。
研究设计与样本
- 纳入4074例60~90岁女性,腰椎或全髋骨密度T值<-2.5(两处均≥-4.0)。
- FREEDOM中按1:1随机接受地舒单抗60mg皮下注射每6个月一次(长期组)或安慰剂(交叉组),合格者可进入延长研究接受地舒单抗60mg皮下注射每6个月一次。
主要发现
- 全部受试者中,NVF发生率(每100受试者年,95%CI)在治疗第1~3年为2.15(1.90~2.43),第4~7年为1.53(1.34~1.75),RR=0.72(0.61~0.86),P<0.001。
- 长期组中,NVF发生率在第1~3年为1.98(1.67~2.34),第4~10年为1.44(1.24~1.66),RR=0.74(0.60~0.93),P=0.008。
- 颌骨坏死合并非典型股骨骨折的发生率为0.06。
临床怎么用
- 对于接受地舒单抗治疗的绝经后骨质疏松女性,长期治疗(>3年且≤10年)可进一步降低非椎体骨折风险。
- 长期治疗期间需关注颌骨坏死和非典型股骨骨折风险,但本研究中合并发生率较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Evidence for further nonvertebral fracture (NVF) reductions with long-term antiresorptive therapy in osteoporosis is lacking. OBJECTIVE: To evaluate NVF risk reduction in subjects receiving ≤10 years of denosumab treatment. DESIGN: Phase 3, randomized, placebo-controlled, 3-year Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial (NCT00089791) and its open-label 7-year extension (NCT00523341). SETTING: One hundred seventy-two study centers worldwide. PATIENTS: Women 60 to 90 years, lumbar spine or total hip bone mineral density T-scores <-2.5 (≥-4.0 at both). INTERVENTIONS: Subjects randomly assigned 1:1 denosumab 60 mg SC Q6M (long-term) or placebo (crossover) in FREEDOM; eligible subjects could enroll in the extension to receive denosumab 60 mg SC Q6M. MAIN OUTCOME MEASURES: NVF Exposure-adjusted subject incidence (per 100 subject-years) during denosumab treatment years 1 to 3 and 4 to 7 (all subjects) and years 4 to 10 (long-term only), and rate ratios (RRs) for years 4 to 7 or 4 to 10 vs 1 to 3. RESULTS: Among 4074 subjects (2343 long-term, 1731 crossover), NVF rates (95% CI) in all subjects were 2.15 (1.90 to 2.43) during years 1 to 3 and 1.53 (1.34 to 1.75) during years 4 to 7 of denosumab treatment [RR (95% CI) = 0.72 (0.61 to 0.86); P < 0.001]; in long-term only were 1.98 (1.67 to 2.34) during years 1 to 3 and 1.44 (1.24 to 1.66) during years 4 to 10 [RR = 0.74 (0.60 to 0.93); P = 0.008]. combined osteonecrosis of the jaw and atypical femoral fracture rate was 0.06. CONCLUSIONS: Long-term denosumab treatment, >3 and ≤10 years, was associated with further reductions in NVF rates compared with the first 3 years.
引用
- Ferrari S, Butler PW, Kendler DL, et al. Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment. J Clin Endocrinol Metab. 2019. PMID: 31125092. doi:10.1210/jc.2019-00271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。